Posters, Publications & White Papers

The investigated ID injection device VAX-ID™ proves to be a good alternative to offer ID vaccination.

The new VAX-ID prototype device was shown to have a high degree of acceptability as well as usability. Further studies with VAX-ID will be conducted using vaccine antigen allowing assessment of immunogenicity and safety. Additionally, these studies will help to further improve VAX-ID in terms of...

The force assessment method and the model can be used to pinpoint needle geometry for intradermal injection devices, tuning comfort for subjects and usability for operators.

Significant differences in skin thickness at the PVF, PDF and deltoid region were seen according to age and BMI. An optimal needle length of 0.7 mm is advised to guarantee intradermal injection in children at all investigated injection sites. ( NCT02727114 ).

Significant differences in skin thickness were seen for the PVF, PDF and deltoid region for gender, and BMI. Age only influenced the skin thickness at deltoid region. A needle length of 1.0mm is best option for intradermal injection at the dorsal forearm ( NCT02363465 ).

Novosanis received a grant from Interreg CrossCare to build a next-generation of its unique and patented intradermal drug delivery device, VAX-ID , in collaboration with living labs Happy Aging (Belgium) and CIC (the Netherlands).

Novosanis is developing the VAX-ID platform suited for accurate drug delivery of e.g. vaccines in the dermal layer of the skin.

Assessment of skin thickness in healthy adult volunteers

Comparison of IM and ID injection of HepB vaccine

New prototype device for intradermal injection VAX-ID